Last reviewed · How we verify
NCT02092714
Molecular Analysis in Tissue Samples From Patients With Advanced or Metastatic Neuroendocrine Tumors
trial testing laboratory biomarker analysis in Neuroendocrine Tumor in 90 participants. Status unknown.
11 April 2018
Quick facts
| Lead sponsor | Fox Chase Cancer Center |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 90 |
| Start date | 16 October 2013 |
| Primary completion | 11 April 2018 |
| Estimated completion | 16 November 2020 |
| Sites | 1 location across United States |
Drugs / interventions tested
- laboratory biomarker analysis — full drug profile →
Conditions studied
- Neuroendocrine Tumor — all drugs for Neuroendocrine Tumor →
Sponsor
Fox Chase Cancer Center — full company profile →
Who can join
18 and older, any sex, with Neuroendocrine Tumor. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This pilot research trial studies molecular analysis in tissue samples from patients with advanced or metastatic neuroendocrine tumors. Studying samples of tissue from patients with neuroendocrine tumors in the lab may help doctors identify mutations to classify disease and plan the best treatment.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Immunotherapy for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a 2021 update.
Kole C, Charalampakis N, Vailas M, Tolia M, et al · · 2022 · cited 10× · PMID 34471940 · DOI 10.1007/s00262-021-03046-8 -
Clinical and Preclinical Advances in Gastroenteropancreatic Neuroendocrine Tumor Therapy.
Crabtree JS. · · 2017 · cited 9× · PMID 29255447 · DOI 10.3389/fendo.2017.00341
Verify or expand the search:
- PubMed search for NCT02092714
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of laboratory biomarker analysis
Trials testing the same drug.
- NCT07492823 — Clinical Applicability of Liquid Biopsy in Chondrosarcoma · not yet recruiting
- NCT07411612 — The Association Between Postoperative Inflammatory and Neurological Serum Biomarker Concentrations and Occurrence of Pos · recruiting
- NCT07375433 — Heart Failure With Preserved Ejection Fraction in Patients With Сhronic Obstructive Pulmonary Disease: Clinical Course a · recruiting
- NCT05388773 — Transoral Surgical Resection Followed by De-escalated Adjuvant IMRT in Resectable p16+ Locally Advanced Oropharynx Cance · Phase 2 · recruiting
- NCT02122172 — Afatinib in Advanced Refractory Urothelial Cancer · Phase 2 · terminated
Other recruiting trials for Neuroendocrine Tumor
Currently open trials in the same condition.
- NCT07132645 — An Investigational Scan ([68Ga] Ga-FAPI-04 PET/CT) for the Imaging of Patients With High-Grade Neuroendocrine Cancer · EARLY_PHASE1 · recruiting
- NCT06788886 — Breathing Practice for Brain and Mental Health in Cancer and Neurodegenerative Diseases · NA · recruiting
- NCT04907643 — Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes · NA · recruiting
- NCT04837885 — Intra-arterial Hepatic (IAH) Infusion of Radiolabelled Somatostatin Analogs in GEP-NET Patients With Dominant Liver Meta · Phase 2 · recruiting
- NCT03375320 — Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors · Phase 3 · active not recruiting
Other Fox Chase Cancer Center trials
Trials by the same sponsor.
- NCT07455032 — Neoadjuvant CADI-05 in Combination With Pembrolizumab for Surgically Resectable Locally Advanced Head and Neck Squamous · Phase 1 · recruiting
- NCT07221942 — Pembrolizumab Maintenance After Enfortumab Vedotin (EV)/Pembro Induction in Front-Line Metastatic Urothelial Carcinoma · Phase 2 · recruiting
- NCT07221058 — Adaptive Radiation Boost for Rectal Cancer · Phase 1 · recruiting
- NCT07167446 — Neuroprotective Potential of Cannabidiol (CBD) in Preventing Oxaliplatin (Ox)-Induced Neuropathy · EARLY_PHASE1 · recruiting
- NCT07219303 — Adaptive Radiation Therapy for Men With Intermediate- or High-Risk Prostate Cancer · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02092714 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fox Chase Cancer Center
- Last refreshed: 23 July 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02092714.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing